Elisa A. Rozeman

机构：The Netherlands Cancer Institute, University Medical Center Utrecht · ORCID：0000-0002-7063-651X

发表论文 178 篇 · 总被引 13824 次 · h-index 34

代表论文

• Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma (2023 · Nature Reviews Clinical Oncology · 被引 50)
• Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo (2024 · European Journal of Cancer · 被引 31)
• IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation (2023 · Journal for ImmunoTherapy of Cancer · 被引 17)
• Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis. (2023 · Journal of Clinical Oncology · 被引 2)
• ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia (2025 · Haematologica · 被引 1)
• Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial (2025 · Research Square · 被引 1)